Display options
Cite
Myrda K, Rozentryt P, Niedziela JT, et al. Clinical and laboratory determinants of low serum level of 25-hydroxyvitamin D during escalation of pharmacotherapy in heart failure patients. Kardiochir Torakochirurgia Pol. 2015;12(3):216-27doi: 10.5114/kitp.2015.54457.
Myrda, K., Rozentryt, P., Niedziela, J. T., Ociessa, A., Kasperova, M., Hudzik, B., Nowak, J. U., & Gąsior, M. (2015). Clinical and laboratory determinants of low serum level of 25-hydroxyvitamin D during escalation of pharmacotherapy in heart failure patients. Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery, 12(3), 216-27. https://doi.org/10.5114/kitp.2015.54457
Myrda, Krzysztof, et al. "Clinical and laboratory determinants of low serum level of 25-hydroxyvitamin D during escalation of pharmacotherapy in heart failure patients." Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery vol. 12,3 (2015): 216-27. doi: https://doi.org/10.5114/kitp.2015.54457
Myrda K, Rozentryt P, Niedziela JT, Ociessa A, Kasperova M, Hudzik B, Nowak JU, Gąsior M. Clinical and laboratory determinants of low serum level of 25-hydroxyvitamin D during escalation of pharmacotherapy in heart failure patients. Kardiochir Torakochirurgia Pol. 2015 Sep;12(3):216-27. doi: 10.5114/kitp.2015.54457. Epub 2015 Sep 28. PMID: 26702277; PMCID: PMC4631913.
Copy Download .nbib Format: NLM
Share it on

Kardiochir Torakochirurgia Pol. 2015 Sep;12(3):216-27. doi: 10.5114/kitp.2015.54457. Epub 2015 Sep 28.

Clinical and laboratory determinants of low serum level of 25-hydroxyvitamin D during escalation of pharmacotherapy in heart failure patients.

Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery

Krzysztof Myrda, Piotr Rozentryt, Jacek T Niedziela, Aneta Ociessa, Maria Kasperova, Bartosz Hudzik, Jolanta U Nowak, Mariusz Gąsior

Affiliations

  1. 3 Department of Cardiology, SMDZ in Zabrze, Medical University of Silesia in Katowice, Silesian Centre for Heart Disease, Zabrze, Poland.

PMID: 26702277 PMCID: PMC4631913 DOI: 10.5114/kitp.2015.54457

Abstract

INTRODUCTION: The activation of the renin-angiotensin-aldosterone (RAA) system is a main element of the pathophysiology of chronic heart failure (CHF), determining its symptoms and prognosis. Vitamin D is an RAA inhibitor, and its deficiency frequently accompanies CHF. The factors determining the concentration of 25-hydroxyvitamin D [25(OH)D] in CHF are not well understood, although an association has been suggested between the deficiency and the advancement of CHF. Also unknown is the influence of therapeutic escalation using recommended agents on the serum level of 25(OH)D. The aim of this study was to examine the incidence of abnormal 25(OH)D concentrations in CHF patients and to establish the clinical and laboratory determinants of low activity of this metabolite.

MATERIAL AND METHODS: The retrospective analysis included the data of 412 CHF patients not receiving optimal pharmacological treatment who were initially in NYHA (New York Heart Association) class III or IV. Over the period of 3 months the therapy was escalated until reaching maximum tolerated doses or those recommended by the current guidelines. After optimizing the therapy, the incidence of 25(OH)D deficiency (< 30 ng/ml) and insufficiency (< 20 ng/ml) was established, and clinical and laboratory determinants for these abnormal concentrations were analyzed.

RESULTS: Normal serum level, insufficiency, and deficiency of 25(OH)D were observed in, respectively, 41.5%, 26.0% and 32.5% of patients. The NYHA class improved by at least 1 class in 63.6% of patients, remained unchanged in 32.8% of patients, and deteriorated in 3.6% of patients. In multivariables analysis, low availability of natural ultraviolet B (UVB) radiation, loss of body mass during the CHF, higher concentrations of phosphates and albumins, and the presence of diabetes increased the risk of 25(OH)D deficiency, while higher concentrations of uric acid reduced this risk. In patients with a positive response to therapy, the concentration of 25(OH)D was borderline significantly higher (p = 0.055), while insufficiency and deficiency were less frequent (p = 0.02) than in patients without a treatment response, but this pertained only to patients with higher exposure to UVB. These differences were not observed in patients with low UVB exposure.

CONCLUSIONS: The concentration of 25(OH)D in CHF patients is not associated with the advancement of the disease, but is strongly determined by the potential availability of UVB radiation. A positive response to therapy increases the concentration of 25(OH)D only in the case of high UVB exposure; other determinants of 25(OH)D level include the patient's metabolic profile and the presence of diabetes.

Keywords: chronic heart failure; vitamin D deficiency

References

  1. Lancet. 2015 Feb 28;385(9970):812-24 - PubMed
  2. J Diabetes Res. 2014;2014:320930 - PubMed
  3. Am Heart J. 2013 Aug;166(2):357-364.e2 - PubMed
  4. Physiol Res. 2011;60 Suppl 1:S155-63 - PubMed
  5. J Clin Endocrinol Metab. 2012 Apr;97(4):1153-8 - PubMed
  6. Eur Heart J. 2015 Aug 7;36(30):1958-66 - PubMed
  7. J Clin Endocrinol Metab. 2008 Oct;93(10):3927-35 - PubMed
  8. J Am Coll Cardiol. 2008 Dec 9;52(24):1949-56 - PubMed
  9. Int J Cardiol. 2014 Oct 20;176(3):852-8 - PubMed
  10. Eur J Heart Fail. 2011 Jun;13(6):619-25 - PubMed
  11. J Cachexia Sarcopenia Muscle. 2015 Dec;6(4):325-34 - PubMed
  12. J Intern Med. 2013 Mar;273(3):253-62 - PubMed
  13. Eur Heart J. 2012 Jul;33(14):1787-847 - PubMed
  14. Am Heart J. 2010 Nov;160(5):893-9 - PubMed
  15. J Clin Invest. 2002 Jul;110(2):229-38 - PubMed
  16. Heart Fail Rev. 2006 Mar;11(1):25-33 - PubMed
  17. Eur J Heart Fail. 2013 Oct;15(10):1173-84 - PubMed
  18. Eur J Heart Fail. 2012 Apr;14(4):357-66 - PubMed
  19. J Cachexia Sarcopenia Muscle. 2010 Dec;1(2):187-194 - PubMed
  20. J Card Fail. 2012 Mar;18(3):233-7 - PubMed
  21. Am J Physiol Cell Physiol. 2013 Jun 1;304(11):C1027-39 - PubMed
  22. Clin Chem. 2009 Jun;55(6):1163-70 - PubMed
  23. J Am Coll Cardiol. 2003 Jan 1;41(1):105-12 - PubMed
  24. South Med J. 2011 May;104(5):325-30 - PubMed
  25. Lancet Diabetes Endocrinol. 2014 Jan;2(1):76-89 - PubMed
  26. Nutr Metab Cardiovasc Dis. 2010 Nov;20(9):633-40 - PubMed
  27. Eur J Heart Fail. 2008 Mar;10(3):321-7 - PubMed
  28. J Steroid Biochem Mol Biol. 2014 Oct;144 Pt A:22-7 - PubMed

Publication Types